Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Income towards Parent Company: 2015-2024

Historic Income towards Parent Company for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$126.9 million.

  • UroGen Pharma's Income towards Parent Company fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
  • UroGen Pharma's Income towards Parent Company amounted to -$126.9 million in FY2024, which was down 24.09% from -$102.2 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Income towards Parent Company ranged from a high of -$102.2 million in FY2023 and a low of -$128.5 million during FY2020.
  • In the last 3 years, UroGen Pharma's Income towards Parent Company had a median value of -$109.8 million in 2022 and averaged -$113.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first increased by 13.75% in 2021, then declined by 24.09% in 2024.
  • Over the past 5 years, UroGen Pharma's Income towards Parent Company (Yearly) stood at -$128.5 million in 2020, then climbed by 13.75% to -$110.8 million in 2021, then grew by 0.94% to -$109.8 million in 2022, then climbed by 6.87% to -$102.2 million in 2023, then fell by 24.09% to -$126.9 million in 2024.